<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1247">
  <stage>Registered</stage>
  <submitdate>28/04/2006</submitdate>
  <approvaldate>8/05/2006</approvaldate>
  <actrnumber>ACTRN12606000162516</actrnumber>
  <trial_identification>
    <studytitle>Randomised placebo controlled trial on the safety and efficacy of BSP-201 in osteoarthritis</studytitle>
    <scientifictitle>Randomised placebo controlled trial on the safety and efficacy to reduce pain, stiffness and physical disfunction of a Sheabutter Extract (BSP-201) in osteoarthritis</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis of the knees and/or hips</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>2250mg/day Sheabutter extract (BSP-201) capsules over a 15 week period</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in Western Ontario and McMaster Universities (WOMAC) score from baseline</outcome>
      <timepoint>Measured at week 5, week 10 and at endpoint at 15 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Comprehensive Osteoarthritis Test (COAT) score. </outcome>
      <timepoint>From baseline, measured at week 5, week 10 and at endpoint at 15 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Quality of Life (Short Form 36).</outcome>
      <timepoint>From baseline, measured at week 5, week 10 and at endpoint at 15 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Paracetamol Usage.</outcome>
      <timepoint>15 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change osteoarthritis biomarkers including markers for fibrinolysis, coagulation, inflammation, cartilage synthesis and degredation and bone formation and resortion. </outcome>
      <timepoint>From baseline, measured at week 10 and endpoint at 15 weeks.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>X-ray and clinical evidence of osteoarthritis of the knees and/or hipsTotal WOMAC score of 30 or more at baseline.Good general health.Adequate venous access.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>A history of trauma with the affected joint.Gout, rheumatoid arthritis or other inflammatory joint condition.Allergy to Sheabutter.Use of anti-arthritic agents before baseline (3 weeks for anti-inflammatory agents inlcuding aspirin, 4 weeks for corticosteroids and 6 weeks for complementary medicines).Liver function tests greater than 2 times the upper limit of normal at baseline.History of alcohol or substance abuse.Females who are pregnant, lactating, planning to become pregnant or unwilling to use birth control during the study.Participants unwilling or unable to comply with the study protocol.Participants who have participated another clincial trial in the last 30 days.History of serious or unstable cardiac, renal, hypertensive, pulmonary, endocrine, neurologic or neuropsychiatric disorder.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Both the active and placebo treatments will be diepensed in identical bottles and be indistinguishable in appearance and odour. the bottles will be randomised, labelled and packaged by sponsor. Only when the study data has been cleaned and the sudy database has been locked will unblinding will occur.</concealment>
    <sequence>The randomisation schedule will be generated and held by the sponsor. A computer generated schedule willbe used to assign wither the active or placebo group in blocks.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>15 weeks duration</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>5/05/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>128</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>BSP Pharma A/S (this is the full name of company)</primarysponsorname>
    <primarysponsoraddress>Denmark</primarysponsoraddress>
    <primarysponsorcountry>Denmark</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>BSP Pharma A/S</fundingname>
      <fundingaddress>Denmark</fundingaddress>
      <fundingcountry>Denmark</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to determin the safety, efficacy and potential modes of action of BSP-201 in adults with osteoarthritis of the knees and/or hips. It will be a randomised, double-blind (both subjects and investigators are blinded), placebo-controlled, parallel study.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Australian Centre for Complementary Medicine Education and Research- Mater Health Services Human Research Ethics Committee</ethicname>
      <ethicaddress>Brisbane premises on the Floor 2, Community Services Building, Mater Health Services, South Brisbane</ethicaddress>
      <ethicapprovaldate />
      <hrec>929E</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Australian Centre for Complementary Medicine Education and Research-University of Queensland Medical Research Ethics Committee</ethicname>
      <ethicaddress>Brisbane premises on the Floor 2, Community Services Building, Mater Health Services, South Brisbane</ethicaddress>
      <ethicapprovaldate />
      <hrec>2006000236</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Australian Centre for Complementary Medicine Education and Research-Southern Cross University Human Research Ethics Committee</ethicname>
      <ethicaddress>Brisbane premises on the Floor 2, Community Services Building, Mater Health Services, South Brisbane</ethicaddress>
      <ethicapprovaldate />
      <hrec>ECN-06-30</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Phillip Cheras</name>
      <address>Floor 2  Community Sevices Building
Mater Health Services
39 Annerley Rd
South Brisbane QLD 4101</address>
      <phone>+61 7 38406111</phone>
      <fax>+61 7 38406119</fax>
      <email>p.cheras@uq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Peta-Anne Paul-Brent</name>
      <address>Floor 2, Community Sevices Building
Mater Health Services
39 Annerley Rd
South Brisbane QLD 4101</address>
      <phone>+61 7 38406112</phone>
      <fax>+61 7 38406119</fax>
      <email>p.kerr@ uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>